Ipamorelin: Research & Studies

Research Overview#

The research literature on Ipamorelin spans hundreds of preclinical studies across multiple therapeutic areas. Below is a structured review of the key studies, systematic reviews, and identified research gaps.

Key Preclinical Studies#

Key studies and findings

• Beck et al., 2014 (International Journal of Colorectal Disease): Prospective, randomized, double-blind, multicenter, placebo-controlled proof-of-concept trial in adults undergoing bowel resection for postoperative ileus (NCT00672074). A total of 117 patients were enrolled; 114 were included in modified intent-to-treat/safety analyses. Ipamorelin 0.03 mg/kg IV twice daily from postoperative day 1 up to day 7 showed no statistically significant improvement in the primary endpoint (time from first dose to tolerance of a standardized solid meal; median 25.3 h vs 32.6 h, p=0.15) and adverse events were comparable to placebo; exploratory efficacy signals were observed in open laparotomy subanalyses without statistical significance (DOI: 10.1007/s00384-014-2030-8).
• Venkova et al., 2009 (Journal of Pharmacology and Experimental Therapeutics): Rat postoperative ileus model testing single-dose and repetitive intravenous bolus regimens of ipamorelin. Cohorts generally included 8–12 rats per group; repetitive dosing (0.1–1 mg/kg) over 48 h significantly accelerated colonic transit, increased fecal pellet output and food intake, and improved 48-h body-weight gain, whereas a single 1 mg/kg dose shortened time to first bowel movement without sustained effects on output or intake (DOI: 10.1124/jpet.108.149211).
• Svensson et al., 2000 (Journal of Endocrinology): Adult female rat study with 12-week continuous subcutaneous infusion via osmotic minipumps comparing ipamorelin, GHRP‑6, growth hormone, and vehicle (n=7–8 per group). Ipamorelin increased total and site-specific bone mineral content and cortical bone dimensions (increased cross-sectional area and cortical bone mineral content) without changes in volumetric BMD; body weight increased and food intake was unchanged (DOI: 10.1677/joe.0.1650569).

The following table consolidates study designs, sample sizes, outcomes, and identifiers for quick reference.

Note on PubMed IDs: PubMed identifiers for these articles were not included in the collected excerpts; therefore, we reported DOIs and detailed bibliographic information instead. If PubMed IDs are essential, a targeted PubMed query would be required to retrieve them beyond the current evidence set.

Musculoskeletal Research#

Summary of the evidence

• Systematic reviews/meta-analyses: A 2016 systematic review and meta-analysis pooled 12 randomized trials (n=1377) of ghrelin receptor agonists in malnourished adults. The class significantly increased energy intake, lean body mass, fat mass, and grip strength versus placebo. Ipamorelin was included among agents considered at the class level, but the meta-analysis did not present ipamorelin-specific pooled estimates or detailed safety synthesis. The authors note limited sample sizes and potential publication bias; adverse events were not quantitatively meta-analyzed.
• Comprehensive/narrative reviews including ipamorelin: A 2020 comprehensive review of growth hormone secretagogues (GHS) summarizes ipamorelin’s pharmacology and development. Ipamorelin produces rapid GH release in humans/animals and showed preclinical prokinetic, orexigenic, and anabolic signals, but Phase II trials in postoperative ileus did not improve time to first tolerated meal or measurable colonic functions, and development was discontinued for that indication. Safety notes from class experience include lack of ACTH/cortisol stimulation with ipamorelin in animal models, CYP3A4 inhibition risk with the related agent tabimorelin, hypotension risk with ulimorelin, and a heart failure signal halting ibutamoren; overall, human efficacy/safety data for ipamorelin remain limited.
• Additional class-oriented reviews: A 2019 narrative review on ghrelin modulation reports preclinical evidence that ipamorelin increases food intake and body weight in rats and cites human class data (e.g., anamorelin) showing dose-related weight increases; safety data for ipamorelin remain sparse in humans. An earlier expert-opinion review details ipamorelin’s preclinical anabolic effects (bone growth/mineral content; protection against glucocorticoid-induced muscle/bone loss), and suggests short-acting peptidyl GHSs like ipamorelin do not stimulate ACTH/cortisol and do not cause significant hyperglycemia; chronic cortisol responses may desensitize.

Conclusions about ipamorelin efficacy

• There is no ipamorelin-specific systematic review or meta-analysis with pooled clinical outcomes. Evidence from a class-level meta-analysis supports efficacy of ghrelin receptor agonists in improving energy intake and body composition in malnourished adults, but this does not isolate ipamorelin’s effect.
• Clinical efficacy for ipamorelin in postoperative ileus was not demonstrated in Phase II trials; endpoints such as time to first tolerated meal and colonic function were not improved versus placebo.
• Preclinical data suggest ipamorelin has orexigenic, prokinetic, and anabolic effects, including weight gain and increases in bone mineral content in animal models.

Conclusions about ipamorelin safety

• Ipamorelin did not stimulate ACTH or cortisol in animal models and did not perturb other pituitary hormones in those settings, indicating a degree of selectivity for GH release. Early-class reviews suggest short-acting peptidyl GHSs like ipamorelin do not cause significant hyperglycemia; however, human safety data specific to ipamorelin remain limited.

• Class-related safety considerations observed with other GHS agents include CYP3A4 inhibition (tabimorelin), hypotension via alpha-1 blockade (ulimorelin), and a heart failure signal (ibutamoren), underscoring the need for careful evaluation of drug interactions and cardiovascular effects for agents in this class; these signals are not specific to ipamorelin but inform class safety context.

• Yes, there is a class-level systematic review/meta-analysis and several comprehensive reviews that include ipamorelin. These indicate that ghrelin receptor agonists as a class improve energy intake and components of body composition in malnourished adults, but ipamorelin-specific clinical efficacy evidence is sparse and negative for postoperative ileus; robust human efficacy data for other indications are lacking. Safety data directly for ipamorelin are limited but suggest selective GH stimulation without ACTH/cortisol activation in animal models; class experience raises potential concerns around CYP3A4 interactions, hypotension, and cardiac safety with certain agents.

Embedded summary table of identified reviews:

Vascular and Cardiovascular#

5. Comprehensive safety program • Trials incorporating serial metabolic panels (glucose, lipids, electrolytes), ECGs, adjudicated cardiovascular endpoints, and oncologic surveillance beyond discharge to detect delayed or rare harms; leverage signals seen with other GHS agents to shape safety monitoring.

6. Translational and mechanistic bridging • Studies that align preclinical biomarkers (e.g., GI transit metrics, inflammatory mediators) with human intermediate endpoints and tissue studies, to improve model‑to‑human predictiveness and refine patient selection.

Embedded summary table

Conclusion The ipamorelin clinical literature is constrained by Phase II only evidence with negative primary outcomes, heterogeneous and short‑horizon endpoints, limited safety characterization, and narrow external validity. Priority research includes adequately powered Phase III and pragmatic studies using standardized GI recovery endpoints, active comparators, dose optimization, comprehensive safety surveillance, and translational biomarker programs to close the preclinical‑clinical gap.

Research Methodology#

We identified three pivotal and frequently cited studies on ipamorelin spanning preclinical pharmacology and human clinical evidence. Where possible, we extracted study designs, sample sizes, and key findings directly from the available texts; however, PubMed IDs were not present in the retrieved excerpts, so we provide DOIs instead and note the limitation.

Research Gaps#

Major methodological limitations and research gaps

1. Trial phase maturity and power • Development halted at Phase II with no Phase III confirmatory trials. The principal multicenter proof‑of‑concept RCT (n≈117) did not significantly shorten time to first tolerated meal; a second Phase II program also reported no significant improvement in colonic functions, and development was discontinued. • Modest sample sizes and exploratory analyses limit power and precision, increasing the risk of false negatives or unstable subgroup signals.

2. Endpoint selection and harmonization • Heterogeneous and sometimes nonstandard endpoints were used (time to standardized meal, first bowel movement, GI‑2 composite, readiness for discharge, length of stay), complicating comparability and meta-analysis. The negative primary endpoint alongside discordant responder analyses underscores endpoint fragility.

3. Duration of follow-up and safety ascertainment • Follow-up was largely confined to the in‑hospital period until discharge. Long‑term safety data are lacking; perioperative TEAEs were common, and two fatal SAEs occurred in the ipamorelin arm in one trial, with a signal for hypokalemia, but there was no systematic surveillance of cardiometabolic or oncologic outcomes after discharge. • More broadly across GHS literature, trials are often short and small, emphasizing endocrine surrogates over adjudicated cardiometabolic outcomes, limiting detection of rare or delayed harms.

4. External validity and population coverage • Eligibility criteria excluded many common comorbidities (e.g., unstable conditions, significant hepatic/renal disease, ECG abnormalities), limiting generalizability to older, frailer, and multimorbid patients who bear the highest POI risk. Surgical heterogeneity (laparoscopic vs open; diverse resections) further dilutes estimates and may mask procedure‑specific effects.

5. Comparator and dosing strategy • Placebo‑controlled designs without active comparators (e.g., alvimopan) leave comparative effectiveness unknown. Dose selection was anchored in early PK/PD and preclinical work; preclinical data suggest regimen sensitivity (benefit with repetitive dosing) that was not thoroughly explored clinically.

6. Preclinical‑to‑clinical translation • Robust benefits in rodent POI models (accelerated transit, improved intake/weight with repetitive dosing) did not translate into clear human efficacy, highlighting species/model limitations and a need for mechanistic biomarkers aligned between models and patients.

What studies are most needed

1. Phase III confirmatory efficacy and safety trial in POI • Multicenter, double‑blind RCT of intravenous ipamorelin vs placebo as add‑on to standardized ERAS pathways in high‑risk open colorectal resections. Primary endpoint: validated GI‑2 composite, with key secondary endpoints including length‑of‑stay, readmissions, first bowel movement, and patient‑reported outcomes. Adequate power with prespecified stratification by surgical approach and age/comorbidities; independent DSMB with interim analyses; 90‑day follow‑up for safety and effectiveness.

2. Active‑comparator and add‑on trials • Randomized trials versus alvimopan or as add‑on to alvimopan/standard prokinetics to define comparative effectiveness and place in therapy; hierarchical testing for GI‑2, length‑of‑stay, and readmissions.

3. Dose‑ranging PK/PD and exposure–response studies in surgical patients • Adaptive designs to optimize dosing (e.g., evaluate repetitive dosing suggested by animal models), using objective motility biomarkers (e.g., manometry, scintigraphy) and model‑informed drug development principles to link exposure to GI‑2 and safety readouts.

4. Pragmatic effectiveness trials with broad inclusion • Real‑world, cluster‑randomized or pragmatic RCTs across ERAS centers that include older adults, women, and patients with common comorbidities (CKD, liver disease, diabetes), with prespecified subgroup analyses to quantify heterogeneity of treatment effect.

Evidence Quality Assessment#

The evidence base for Ipamorelin currently consists primarily of preclinical studies. On the evidence hierarchy:

• Systematic reviews/meta-analyses: Limited availability
• Randomized controlled trials (human): Not completed
• Animal studies: Extensive body of research
• In vitro studies: Multiple cell culture experiments
• Case reports: Limited anecdotal evidence

Related Reading#

• Ipamorelin overview and research guide
• Ipamorelin dosing protocols
• Ipamorelin molecular structure